ERS International Congress, Milan 2017

---

PAH and CTEPH

Thematic Poster
Chairs: C. Fernandes (Sao Paulo/Sp, Brazil), M. Delcroix (Leuven, Belgium), P. Hassoun (Baltimore, United States of America), H. Ghofrani (Giessen, Germany)

Evaluation of a novel clinic for management of Chronic Thromboembolic Pulmonary Disease (CTED) and associated Pulmonary Hypertension (CTEPH). A. Roddick (London, United Kingdom)
Quality of life and physical functioning in chronic thromboembolic pulmonary hypertension (CTEPH):  the impact of treatment D. Cavalet Blanco (PORTO ALEGRE/RS, Brazil)
Real-life data on the medical therapy of pulmonary arterial and chronic thromboembolic pulmonary hypertension E. Schwarz (Zürich, Switzerland)
The use of new anticoagulants in CTEPH F. Gavilanes Oleas (Sao Paulo/Sp, Brazil)
Chronic thromboembolic pulmonary hypertension (CTEPH) and coagulation defects: Before and after treatment E. Vrigkou (Athens, Greece)
Pulmonary perfusion changes after Balloon Pulmonary Angioplasty for chronic thromboembolic pulmonary hypertension A. Hachulla (Geneva, Switzerland)
Liquid biopsy for Chronic Thromboembolic Pulmonary Hypertension: Circulating microRNA profile by Next Generation Sequencing A. Todorovic Fabro (Ribeirao Preto/Sp, Brazil)
Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia T. Martynyuk (Moscow, Switzerland)
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) L. Nicod (Lausanne, Switzerland)
Fluid challenge test and pulmonary haemodynamics in patients with systemic sclerosis M. D'Alto (Napoli, Na, Italy)
Incidence of new pulmonary hypertension and determining factors during follow-up of patients with systemic sclerosis after negative right heart catheterisation S. Harutyunova (Heidelberg, Germany)
REPLACE: A prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal M. Hoeper (Hannover, Germany)
Impact of insomnia on exercise capacity and quality of life in patients with pulmonary arterial hypertension K. Swinnen (Leuven, Belgium)
PHA-UK living with Pulmonary Hypertension 2016 Survey C. Billings (Sheffield, United Kingdom)
Evaluation of thyroid function in pulmonary arterial hypertension G. Cueto Robledo (México D.F, Mexico)
Undifferentiated connective tissue disease at risk for systemic sclerosis: is heart function already impaired? M. D'Alto (Napoli, Na, Italy)
VENTASWITCH study: Switching from Ventavis (iloprost) V10 to V20 improves inhalation behaviour in patients with pulmonary arterial hypertension (PAH) M. Richter (Giessen, Germany)
Pregnancy in PAH associated with congenital heart disease: 6-year clinical cases series from the referral center A. Bautin (St Petersburg, Russian Federation)
Managing pregnancy in pulmonary hypertension using a multi-professional approach: a 16-year experience in a specialist referral centre L. ten Klooster (Nieuwegein, Netherlands)
Modern management of portopulmonary hypertension in children : case series of an expert center F. Lador (Genève 14, Switzerland)